Clinical TrialJun 14, 2026, 07:30 PM
Ascentage Pharma Presents Positive Clinical Data for Olverembatinib & Lisaftoclax
AI Summary
Ascentage Pharma announced positive clinical updates for its core assets, olverembatinib and lisaftoclax, at the 31st European Hematology Association (EHA2026) Congress. Olverembatinib showed deep and durable responses in CML and robust clinical response in Ph+ ALL, including a 94.4% CR/CRi rate in newly diagnosed Ph+ ALL. Lisaftoclax demonstrated promising efficacy in myeloid neoplasms with a 72% CR/CRi rate in AML and clinical activity in R/R CLL/SLL with a median PFS of 23.9 months. The data validates the therapeutic value and potential of these therapies.
Key Highlights
- Olverembatinib showed 76.2% CCyR and 47.6% MMR as 2nd-line therapy in CML-CP without T315I mutation.
- Switching to olverembatinib resulted in a 54.3% 6-month MMR rate in CML-CP patients failing at least two TKIs.
- Olverembatinib combined with chemotherapy achieved 94.4% CR/CRi and 93.1% MRD-negativity in newly diagnosed Ph+ ALL.
- Chemotherapy-free combination of olverembatinib + lisaftoclax yielded 88.9% ORR in pediatric R/R Ph+ ALL.
- Lisaftoclax demonstrated 72% CR/CRi rate in AML patients with myeloid neoplasms in a real-world study.
- Lisaftoclax achieved 62.5% ORR and 23.9 months median PFS in R/R CLL/SLL patients refractory to BTKi.
- Both olverembatinib and lisaftoclax showed manageable safety profiles across various studies.
Price Impact
More from AAPG